Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax.
Saved in:
| Title: | Outcomes of adult patients with newly diagnosed IDH-mutated AML treated with intensive chemotherapy and venetoclax. |
|---|---|
| Authors: | Croden J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jen WY; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Marvin-Peek J; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Xiao L; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Bouligny IM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Loghavi S; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Borthakur G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Daver NG; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Abbas HA; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Takahashi K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Sasaki K; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Pemmaraju N; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Short NJ; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Hammond D; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Jabbour E; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Masarova L; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Chien KS; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Issa GC; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Montalban-Bravo G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Yilmaz M; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Maiti A; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Alvarado-Valero Y; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Garcia-Manero G; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Ravandi F; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Konopleva MY; Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, New York, USA., Kantarjian HM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Kadia TM; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., DiNardo CD; Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. CDiNardo@mdanderson.org. |
| Source: | Leukemia [Leukemia] 2025 Oct; Vol. 39 (10), pp. 2538-2541. Date of Electronic Publication: 2025 Aug 14. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Publishing Group, Specialist Journals Country of Publication: England NLM ID: 8704895 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1476-5551 (Electronic) Linking ISSN: 08876924 NLM ISO Abbreviation: Leukemia Subsets: MEDLINE; In Process |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
